Malathi Hari

Statistics

Publications

Citations

688

H-Index

Active since

2003

Affiliations

The University of Texas at Austin(Current)

Texas Medical Center

Ziopharm Oncology (United States)

Malathi Hari is an author at The University of Texas at Austin specializing in microtubule-associated proteins, chemotherapy resistance, and cancer pharmacology.

Publications per year

2003–2013

Publications

Expression of class III β‐tubulin reduces microtubule assembly and confers resistance to paclitaxel

Malathi Hari, Hailing Yang, Changqing Zeng et al. · Cell Motility and the Cytoskeleton · 2003 · 149 citations

Life Sciences, Cell Biology, Cancer Pharmacology +14

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules

Malathi Hari, Frank Loganzo, Tami Annable et al. · Molecular Cancer Therapeutics · 2006 · 147 citations

Medicine, Oncology, Pharmacology +17

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Frank Loganzo, Carolyn Discafani, Tami Annable et al. · PubMed · 2003 · 137 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.

Malathi Hari, Yaqing Wang, Sudha Veeraraghavan et al. · PubMed · 2003 · 91 citations

Medicine, Cancer Biology, Oncology +17

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Frank Loganzo, Malathi Hari, Tami Annable et al. · PubMed · 2004 · 39 citations

Medicine, Oncology, Pharmacology +14

1–5 of 10